Cerus Corporation CERS

CERS Company Overview

Cerus Corporation is a biomedical products company focused on developing and commercializing pathogen reduction technologies for blood safety. The company operates within the healthcare, medical technology, and transfusion medicine industries, with its primary commercial platform centered on the INTERCEPT Blood System, a pathogen inactivation technology designed to reduce the risk of transfusion-transmitted infections in blood components. Cerus generates revenue primarily through sales of disposable kits, illuminators, and related support services used by blood centers, hospitals, and transfusion service providers.

The company’s core markets include blood collection organizations, national blood systems, hospitals, and healthcare agencies across North America, Europe, the Middle East, and selected Asia-Pacific markets. Cerus has positioned itself as a specialized leader in pathogen reduction technology, benefiting from regulatory approvals in multiple jurisdictions and long-term relationships with blood service operators. Founded in 1991 and headquartered in Concord, California, Cerus evolved from an early-stage biotechnology company into a commercial-stage medical technology company focused primarily on blood safety and transfusion support infrastructure.